Full text is available at the source.
Abstract
Tirzepatide is a dual agonist that has demonstrated efficacy in weight loss and cardiovascular improvement.
- The specific impact of tirzepatide on the occurrence of atrial fibrillation in individuals with overweight or obesity is not well understood.
- Tirzepatide targets glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors.
- Previous studies have shown tirzepatide's effectiveness in facilitating weight loss.
- Tirzepatide is associated with improved cardiovascular outcomes.
Simplified